exidavnemab vs LY3962681
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: alpha-synuclein · full Parkinson's Disease pipeline
exidavnemab
Developed by BioArctic AB and partners
NCT06671938 · Phase 2 · completed
This is a randomized, double-blind, placebo-controlled trial, but it enrolled only 38 participants split across dose cohorts, its primary endpoint measures adverse-event incidence rather than efficacy, and results have not yet been posted, so no conclusion about benefit can be drawn. Its registered primary outcome on ClinicalTrials.gov is "Number of participants with adverse events (AEs) and serious adverse events (SAEs).". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
No aligned efficacy figure on record for this race.
LY3962681
Developed by Eli Lilly and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: July 2030 · NCT06565195 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | exidavnemab | LY3962681 |
|---|---|---|
| OFF time, change | —Not reported | —Not reported |
| ON time without troublesome dyskinesia, change | —Not reported | —Not reported |
| UPDRS Part III, change | —Not reported | —Not reported |
| MDS-UPDRS Part II, change | —Not reported | —Not reported |
OFF time, change
- exidavnemab
- —Not reported
- LY3962681
- —Not reported
ON time without troublesome dyskinesia, change
- exidavnemab
- —Not reported
- LY3962681
- —Not reported
UPDRS Part III, change
- exidavnemab
- —Not reported
- LY3962681
- —Not reported
MDS-UPDRS Part II, change
- exidavnemab
- —Not reported
- LY3962681
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
exidavnemab: no structured comparison results are available for Parkinson's Disease.
LY3962681: no structured comparison results are available for Parkinson's Disease.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: exidavnemab's landscape · LY3962681's landscape